Iridex transilluminated probe for glaucoma treatment receives CE Mark approval

The probe is powered by the company's Cyclo G6 glaucoma laser system.

Mar 20th, 2018

Iridex (Mountain View, CA) has received CE Mark regulatory approval in Europe for its G-Probe Illuminate probe, which combines transillumination and a laser fiber for targeted transscleral cyclophotocoagulation (CPC; a glaucoma treatment). The probe, which received FDA clearance and was launched in early 2017, is powered by the company's Cyclo G6 glaucoma laser system. The system features built-in transillumination to optimize placement of the probe and therapeutic outcomes.

Related: Iridex ophthalmic laser system for glaucoma treatment receives CE Mark approval

Studies have shown the ciliary body, the target tissue for a CPC treatment, naturally varies in location between patients, and cases of abnormal ocular size, high myopia, and post-corneal transplants generate even more challenges. The G-Probe Illuminate may improve the ability of physicians to locate the ciliary body and deliver the laser treatment in a more targeted manner.

The G-Probe Illuminate may be used in the operating room or as an outpatient, office-based procedure for treating glaucoma.

For more information, please visit www.iridex.com.

More in Biophotonics Tools